PER 1.27% 8.0¢ percheron therapeutics limited

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-134

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,710 Posts.
    lightbulb Created with Sketch. 1097
    From the AGM preso Dec2020...

    ....As reported, the recent financing has provided capital to support the preparatory work for the trial up to trial initiation, therefore the major costs associated with the conduct of the trial are not anticipated to come through until later in 2021. In the interim, the company will look at funding options for the trial while continuing with its planned corporate engagement which may present as part of the financing option.

    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.001(1.27%)
Mkt cap ! $82.94M
Open High Low Value Volume
8.0¢ 8.3¢ 7.9¢ $461.5K 5.711M

Buyers (Bids)

No. Vol. Price($)
6 844186 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 292500 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.